These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 35072756)

  • 1. Characterization of recent non-fentanyl synthetic opioids via three different in vitro µ-opioid receptor activation assays.
    Vandeputte MM; Persson M; Walther D; Vikingsson S; Kronstrand R; Baumann MH; Gréen H; Stove CP
    Arch Toxicol; 2022 Mar; 96(3):877-897. PubMed ID: 35072756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro functional characterization of a panel of non-fentanyl opioid new psychoactive substances.
    Vandeputte MM; Cannaert A; Stove CP
    Arch Toxicol; 2020 Nov; 94(11):3819-3830. PubMed ID: 32734307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elucidating the harm potential of brorphine analogues as new synthetic opioids: Synthesis, in vitro, and in vivo characterization.
    Vandeputte MM; Bilel S; Tirri M; Corli G; Bassi M; Layle NK; Fantinati A; Walther D; Iula DM; Baumann MH; Stove CP; Marti M
    Neuropharmacology; 2024 Dec; 260():110113. PubMed ID: 39154855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative neuropharmacology of structurally distinct non-fentanyl opioids that are appearing on recreational drug markets worldwide.
    Vandeputte MM; Tsai MM; Chen L; Glatfelter GC; Walther D; Stove CP; Shi L; Baumann MH
    Drug Alcohol Depend; 2023 Aug; 249():109939. PubMed ID: 37276825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First identification, chemical analysis and pharmacological characterization of N-piperidinyl etonitazene (etonitazepipne), a recent addition to the 2-benzylbenzimidazole opioid subclass.
    Vandeputte MM; Verougstraete N; Walther D; Glatfelter GC; Malfliet J; Baumann MH; Verstraete AG; Stove CP
    Arch Toxicol; 2022 Jun; 96(6):1865-1880. PubMed ID: 35449307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alkoxy chain length governs the potency of 2-benzylbenzimidazole 'nitazene' opioids associated with human overdose.
    Glatfelter GC; Vandeputte MM; Chen L; Walther D; Tsai MM; Shi L; Stove CP; Baumann MH
    Psychopharmacology (Berl); 2023 Dec; 240(12):2573-2584. PubMed ID: 37658878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological evaluation and forensic case series of N-pyrrolidino etonitazene (etonitazepyne), a newly emerging 2-benzylbenzimidazole 'nitazene' synthetic opioid.
    Vandeputte MM; Krotulski AJ; Walther D; Glatfelter GC; Papsun D; Walton SE; Logan BK; Baumann MH; Stove CP
    Arch Toxicol; 2022 Jun; 96(6):1845-1863. PubMed ID: 35477798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro μ-opioid receptor activation potential of U10 and β-U10, positional isomers of the synthetic opioid naphthyl U-47700.
    Vandeputte MM; Stove CP
    Drug Test Anal; 2024 Mar; 16(3):323-326. PubMed ID: 37482925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection, chemical analysis, and pharmacological characterization of dipyanone and other new synthetic opioids related to prescription drugs.
    Vandeputte MM; Walton SE; Shuda SA; Papsun DM; Krotulski AJ; Stove CP
    Anal Bioanal Chem; 2023 Sep; 415(21):5165-5180. PubMed ID: 37173408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological characterization of novel synthetic opioids: Isotonitazene, metonitazene, and piperidylthiambutene as potent μ-opioid receptor agonists.
    De Luca MA; Tocco G; Mostallino R; Laus A; Caria F; Musa A; Pintori N; Ucha M; Poza C; Ambrosio E; Di Chiara G; Castelli MP
    Neuropharmacology; 2022 Dec; 221():109263. PubMed ID: 36154843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of the μ- and κ-opioid receptor activation by eight new synthetic opioids using the [
    Otte L; Wilde M; Auwärter V; Grafinger KE
    Drug Test Anal; 2022 Jul; 14(7):1187-1199. PubMed ID: 35142070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of structure-activity relationships and biased agonism at the Mu opioid receptor of novel synthetic opioids using a novel, stable bio-assay platform.
    Vasudevan L; Vandeputte M; Deventer M; Wouters E; Cannaert A; Stove CP
    Biochem Pharmacol; 2020 Jul; 177():113910. PubMed ID: 32179045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vitro Functional Profiling of Fentanyl and Nitazene Analogs at the μ-Opioid Receptor Reveals High Efficacy for Gi Protein Signaling.
    Tsai MM; Chen L; Baumann MH; Canals M; Javitch JA; Lane JR; Shi L
    ACS Chem Neurosci; 2024 Feb; 15(4):854-867. PubMed ID: 38345920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel nanobody-based bio-assay using functional complementation of a split nanoluciferase to monitor Mu- opioid receptor activation.
    Vasudevan L; Stove CP
    Anal Bioanal Chem; 2020 Nov; 412(29):8015-8022. PubMed ID: 32926202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicological and pharmacological characterization of novel cinnamylpiperazine synthetic opioids in humans and in vitro including 2-methyl AP-237 and AP-238.
    Fogarty MF; Vandeputte MM; Krotulski AJ; Papsun D; Walton SE; Stove CP; Logan BK
    Arch Toxicol; 2022 Jun; 96(6):1701-1710. PubMed ID: 35275255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are the N-demethylated metabolites of U-47700 more active than their parent compound? In vitro μ-opioid receptor activation of N-desmethyl-U-47700 and N,N-bisdesmethyl-U-47700.
    Nordmeier F; Cannaert A; Stove CP; Schmidt PH; Meyer MR; Schaefer N
    Drug Test Anal; 2022 Apr; 14(4):713-717. PubMed ID: 34669261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Binding preference at the μ-opioid receptor underlies distinct pharmacology of cyclopropyl versus valeryl analogs of fentanyl.
    Xie B; Le Rouzic VP; Goldberg A; Tsai MM; Chen L; Zhang T; Sinha A; Pan YX; Baumann MH; Shi L
    Neuropharmacology; 2023 Apr; 227():109442. PubMed ID: 36731721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, biological, and structural explorations of a series of μ-opioid receptor (MOR) agonists with high G protein signaling bias.
    Yang Y; Wang Y; Zuo A; Li C; Wang W; Jiang W; Zhang X; Che X; Zhang Y; Wu W; Cen X; Wang H; Tian J
    Eur J Med Chem; 2022 Jan; 228():113986. PubMed ID: 34802839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro functional assays as a tool to study new synthetic opioids at the μ-opioid receptor: Potential, pitfalls and progress.
    Vandeputte MM; Vasudevan L; Stove CP
    Pharmacol Ther; 2022 Jul; 235():108161. PubMed ID: 35183593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic Characterization of Substituted Nitazenes at
    Kozell LB; Eshleman AJ; Wolfrum KM; Swanson TL; Bloom SH; Benware S; Schmachtenberg JL; Schutzer KA; Schutzer WE; Janowsky A; Abbas AI
    J Pharmacol Exp Ther; 2024 Apr; 389(2):219-228. PubMed ID: 38453524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.